Converge Bio secures $25 million to scale AI-driven drug discovery

Traditional drug discovery and optimisation still rely on slow, iterative laboratory work. Screening vast libraries of variants and interpreting transcriptomic data to predict patient responses can easily stretch into multi‑year programmes.

Founded in 2024 and headquartered between Boston and Tel Aviv, Converge Bio is developing an LLM stack comprising foundation models that have been fine-tuned to understand different 'biological languages', thus enabling a faster drug discovery process. Its generative and predictive models, which are trained using molecular and multi-omics data, can design or refine antibodies in various formats, predict binding and developability issues, optimise expression constructs and simulate cell- and patient-level responses using raw gene expression data.

The company recently secured a $25 million Series A funding round, led by Bessemer Venture Partners and joined by TLV Partners, Saras Capital, Vintage Investment Partners, and other investors from Meta, OpenAI, and Wiz. The funding will enhance Converge Bio’s model suite and accelerate product innovation.

and deepen integrations with pharma pipelines.

Sources: Converge Bio | Crunchbase

Founders: Dov Gertz, Oded Kalev, Iddo Weiner